NCT05102747: Stereotactic Radiotherapy in Oligometastatic Brain Disease: a Randomised Phase III Study Comparing Hypofractionated Stereotactic Radiation Therapy (3*10 Gy) to the Historical Single-dose Radiosurgery (1*20 to 25 Gy) With Medico-economic Evaluation

NCT05102747
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Not Applicable
Drug Category: Radiation Therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patients must have had a partial or complete response resulting in stable disease outside of the brain (extracranially)
Exclusions: Patients with metastases in the brain stem; Patients who have had whole brain radiation therapy; Patients with progressive unstable extracranial disease
https://ClinicalTrials.gov/show/NCT05102747

Comments are closed.

Up ↑